bioAffinity Technologies has signed a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, to market its CyPath Lung diagnostic test to federal healthcare agencies, including VA medical centers. This partnership leverages AvMEDICAL's existing sales team and government procurement channels, significantly expanding bioAffinity's commercial reach into the government healthcare market.
bioAffinity Technologies (BIAF) has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business. This agreement is significant because it provides BIAF with immediate access to the federal healthcare market, particularly VA medical centers, for its CyPath Lung diagnostic test. AvMEDICAL's established government procurement channels and existing sales team are expected to accelerate the commercialization of CyPath Lung within this sector. This represents a short-term opportunity for increased sales and market penetration for BIAF, potentially leading to long-term revenue growth and broader adoption of its diagnostic technology. For traders, this could signal a positive catalyst for BIAF's stock as it opens up a new, substantial revenue stream.